It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Fatty acid amide hydrolase (FAAH) is a membrane-bound homodimeric enzyme that in vivo controls content and biological activity of N-arachidonoylethanolamine (AEA) and other relevant bioactive lipids termed endocannabinoids. Parallel orientation of FAAH monomers likely allows both subunits to simultaneously recruit and cleave substrates. Here, we show full inhibition of human and rat FAAH by means of enzyme inhibitors used at a homodimer:inhibitor stoichiometric ratio of 1:1, implying that occupation of only one of the two active sites of FAAH is enough to fully block catalysis. Single W445Y substitution in rat FAAH displayed the same activity as the wild-type, but failed to show full inhibition at the homodimer:inhibitor 1:1 ratio. Instead, F432A mutant exhibited reduced specific activity but was fully inhibited at the homodimer:inhibitor 1:1 ratio. Kinetic analysis of AEA hydrolysis by rat FAAH and its F432A mutant demonstrated a Hill coefficient of ~1.6, that instead was ~1.0 in the W445Y mutant. Of note, also human FAAH catalysed an allosteric hydrolysis of AEA, showing a Hill coefficient of ~1.9. Taken together, this study demonstrates an unprecedented allosterism of FAAH, and represents a case of communication between two enzyme subunits seemingly controlled by a single amino acid (W445) at the dimer interface. In the light of extensive attempts and subsequent failures over the last decade to develop effective drugs for human therapy, these findings pave the way to the rationale design of new molecules that, by acting as positive or negative heterotropic effectors of FAAH, may control more efficiently its activity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Teramo, Faculty of Biosciences, and Technology for Food Agriculture and Environment, Teramo, Italy (GRID:grid.17083.3d) (ISNI:0000 0001 2202 794X)
2 European Center for Brain Research (CERC)/Santa Lucia Foundation, Rome, Italy (GRID:grid.17083.3d); University of Teramo, Faculty of Veterinary Medicine, Teramo, Italy (GRID:grid.17083.3d) (ISNI:0000 0001 2202 794X)
3 University of Teramo, Faculty of Veterinary Medicine, Teramo, Italy (GRID:grid.17083.3d) (ISNI:0000 0001 2202 794X)
4 University of Pompeu Fabra and Icrea, Barcelona Biomedical Research Park (PRBB), Barcelona, Spain (GRID:grid.5612.0) (ISNI:0000 0001 2172 2676)
5 Tor Vergata University of Rome, Department of Experimental Medicine and Surgery, Rome, Italy (GRID:grid.6530.0) (ISNI:0000 0001 2300 0941)
6 European Center for Brain Research (CERC)/Santa Lucia Foundation, Rome, Italy (GRID:grid.5612.0); Department of Medicine - Campus Bio-Medico University of Rome, Rome, Italy (GRID:grid.9657.d) (ISNI:0000 0004 1757 5329)